Ausgabe 1/2012
Inhalt (14 Artikel)
Open Access
Letter to the Editor
Letter to the Editor: Regarding “The Utility and Limitations of FRAX: A US Perspective”
Edward Czerwinski
Letter to the Editor
Reply to the Letter by E. Czerwinski Regarding “The Utility and Limitations of FRAX: A US Perspective”
Stuart L. Silverman, Andrew D. Calderon
Current Therapeutics (SL Silverman, Section Editor)
Vitamin D in the New Millennium
Sunil J. Wimalawansa
Current Therapeutics (SL Silverman, Section Editor)
Data from Extension Trials: Denosumab and Zoledronic Acid
Robin K. Dore
Current Therapeutics (SL Silverman, Section Editor)
Assessment of Fracture Risk
Sanford Baim, William D. Leslie
Current Therapeutics (SL Silverman, Section Editor)
Can PET-CT Imaging and Radiokinetic Analyses Provide Useful Clinical Information on Atypical Femoral Shaft Fracture in Osteoporotic Patients?
C. Haile Chesnut IV, Charles H. Chesnut III
Current Therapeutics (SL Silverman, Section Editor)
Osteoporosis After Transplantation
Carolina A. Moreira Kulak, Victoria Z. Cochenski Borba, Jaime Kulak Júnior, Melani Ribeiro Custódio
Current Therapeutics (SL Silverman, Section Editor)
Clinical Use of Bone Turnover Markers to Monitor Pharmacologic Fracture Prevention Therapy
John T. Schousboe, Douglas C. Bauer
Future Therapeutics (P Miller, Section Editor)
Sclerostin: Therapeutic Horizons Based Upon Its Actions
Aline G. Costa, John P. Bilezikian
Future Therapeutics (P Miller, Section Editor)
Inhibition of Cathepsin K for Treatment of Osteoporosis
Steven Boonen, Elizabeth Rosenberg, Frank Claessens, Dirk Vanderschueren, Socrates Papapoulos
Future Therapeutics (P Miller, Section Editor)
Nitric Oxide Donors for the Treatment of Osteoporosis
Sophie A. Jamal, Celeste J. Hamilton
Future Therapeutics (P Miller, Section Editor)
Potential Role for Therapies Targeting DKK1, LRP5, and Serotonin in the Treatment of Osteoporosis
Wei Zhang, Matthew T. Drake